$OBIO

Sherman Darren sold $58K of OBIO

Sherman Darren (See Remarks) sold 15,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.87 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sherman Darren
Published Jun 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OBIO
Neutral
high confidence
Mentioned
$OBIO
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The newest fact is the reported open-market sale amount and price, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental catalyst in the filing text.

03

What to watch

The filing does not state any change in business outlook, and the text provides only the sale details, not context like option exercises, tax planning, or total compensation mix.

Relevance 2/10Novelty 3/10Timing: filed 2026-06-02 for a 2026-06-01 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Orchestra BioMed Holdings, Inc.

Company-level read

Ticker impact

$OBIONeutralHigh confidence
Context

Orchestra BioMed Holdings disclosed an officer/director open-market sale of 15,000 shares at $3.87 on a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more about sentiment than new company information.

Evidence & confidence

Form 4 reports a completed sale with no accompanying operational, financial, or regulatory disclosure in the text, and explicitly notes a pre-arranged 10b5-1 plan.

Market effects

No sector-wide implications; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical liquidity events, so the market may overreact if it treats the sale as a bearish signal.

Key entities

  • Orchestra BioMed Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure (OBIO).

  • Sherman Darren

    Officer and director who sold 15,000 shares on 2026-06-01 under a 10b5-1 plan.

Related articles